Skip to main content
HairCited

Minoxidil in the treatment of androgenetic alopecia.

Andy Goren, Ty Naccarato
Review Dermatologic therapy 2018 63 цитирований
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D30155952'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Тип исследования
Review
Вмешательство
Minoxidil in the treatment of androgenetic alopecia. Up to 5% concentration (OTC approved in US)
Препарат сравнения
Placebo
Направление эффекта
Positive
Риск систематической ошибки
Unclear

Abstract

The National Institutes of Health (US NIH, 2018) estimates that in the US approximately 50 million men and 30 million women suffer from AGA (also known as pattern hair loss). Minoxidil is the only topical drug for the treatment of both female and male pattern hair loss. In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings of the pivotal studies used in support of the drug's approval as well as recent discoveries and novel developments in the use of minoxidil for the treatment of AGA.

Used In Evidence Reviews

Similar Papers